Natural Compound

Lemon Balm

Melissa officinalis

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

300–600 mg per day (Cyracos standardized extract)

watchEffect Window

Acute effects within 30-60 minutes.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Lemon balm is a mild calming herb with the clearest newer evidence in sleep-quality support from standardized extracts, not as a broad all-purpose anti-anxiety agent.

Human studies suggest lemon balm can modestly improve sleep quality and, in some formulation-specific settings, emotional-distress outcomes. The cleanest blinded signal remains short-term sleep support from standardized bioavailable extracts. Newer studies also suggest phospholipid formulations may improve mood and sleep over 3 weeks and that an acute 300 mg extract can help preserve difficult-task performance under cognitive overload, but those findings do not justify broad all-purpose anti-anxiety or cognition claims. Effects remain formulation specific and generally milder than supplement marketing implies.

Rosmarinic-acid-rich extracts may inhibit GABA transaminase and influence cholinergic signaling. The best recent human evidence supports mild sleep-quality effects with standardized formulations rather than broad daytime anxiolytic claims.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Moderate reduction in acute stress and anxiety with improved calmness.

Secondary Outcomes

  • Sleep quality support (especially with valerian)
  • Mild cognitive processing benefits
  • Potential antiviral activity against herpes simplex

Safety

Contraindications and Interactions

Contraindications

  • Hypothyroidism
  • Hashimoto's thyroiditis
  • Thyroid medication use
  • Pregnancy
  • Lactation (caution)

Side effects

  • Nausea
  • Vomiting
  • Abdominal pain
  • GI discomfort
  • Wheezing
  • Headache
  • Dizziness (rare)
  • Increased appetite
  • Sedation
  • Reduced alertness

Interactions

  • Thyroid medications (Theoretical/Unknown) - May antagonize thyroid replacement therapy and reduce levothyroxine effectiveness.
  • Sedatives and CNS depressants (Theoretical/Unknown) - May increase sedation and reduce alertness.
  • Anticholinergic drugs (Theoretical/Unknown) - May reduce anticholinergic effectiveness.
  • Drugs that are CYP2C19 substrates (Theoretical/Unknown) - Rosmarinic acid may inhibit CYP2C19 and increase substrate exposure.
  • Drugs that are CYP2E1 substrates (Theoretical/Unknown) - Rosmarinic acid may inhibit CYP2E1 and increase substrate exposure.
  • Glaucoma medications (Theoretical/Unknown) - Potential interaction. Monitor clinical response.
  • Supplements that cause drowsiness/sedation (Theoretical/Unknown) - May increase sedation when combined.
  • Anticholinergic supplements (Theoretical/Unknown) - May reduce supplement effectiveness.
  • Supplements that increase thyroid hormones (Theoretical/Unknown) - May blunt intended thyroid-hormone effects.

Avoid if

  • Hypothyroidism
  • Hashimoto's thyroiditis
  • Thyroid replacement therapy
  • Pregnancy considerations
  • Lactation considerations

Evidence

Study-level References

lemon-balm-SRC-000Randomized double-blind placebo-controlled crossover trial
Sourceopen_in_new

Di Pierro F, Sisti D, Rocchi M, et al. Effects of Melissa officinalis Phytosome on Sleep Quality: Results of a Prospective, Double-Blind, Placebo-Controlled, and Cross-Over Study. Nutrients. 2024;16(23):4199. doi:10.3390/nu16234199. PMID:39683592.

Population: Adults with fatigue on waking and unrefreshing sleep enrolled at two Italian clinical centers.

Dose protocol: Standardized Melissa officinalis Phytosome in a double-blind crossover design

Key findings: Improved Insomnia Severity Index scores, increased slow-wave sleep, and improved self-reported sleep quality versus placebo.

Notes: Best blinded current human anchor is sleep quality rather than daytime stress relief.

Paper content

This modern lemon-balm study used a double-blind crossover design in 30 adults and tested a specific 200 mg phytosome formulation for two weeks at a time. Active treatment lowered ISI scores by 2.9 points versus placebo, increased slow-wave sleep, decreased REM time, and markedly improved subjective sleep ratings, while anxiety scores and physical activity did not change. The crossover design, washout analysis, and formulation specificity make it a better anchor for sleep-quality claims than older acute calmness studies, but the sample was small and the trial duration was short.

lemon-balm-pmid-37927585Randomized, double-blind, placebo-controlled trial.
Sourceopen_in_new

Bano A, Hepsomali P, Rabbani F, Farooq U, et al. The possible calming effect of subchronic supplementation of a standardised phospholipid carrier-based Melissa officinalis L. extract in healthy adults with emotional distress and poor sleep conditions. Front Pharmacol. 2023;14:1250560. doi:10.3389/fphar.2023.1250560. PMID:37927585.

Population: Healthy adults with moderate depression, anxiety, stress, or poor sleep quality.

Dose protocol: 400 mg/day phospholipid-based Melissa officinalis extract for 3 weeks (n=100)

Key findings: Significant improvements in depression, anxiety, stress, affect, wellbeing, and quality of life versus placebo (all P<0.001). No serious adverse events.

Notes: Formulation-specific phospholipid carrier. Short duration but large effect sizes.

Paper content

This 3-week randomized, double-blind, placebo-controlled trial tested 400 mg daily of a phospholipid carrier-based Melissa officinalis extract in 100 healthy adults with moderate emotional distress or poor sleep. The active group showed significant improvements in depressive mood, anxiety, stress, positive and negative affect, mental wellbeing, and quality of life (all P<0.001) versus placebo. No serious adverse events were reported. The study supports a calming effect of standardized lemon balm extract over a short treatment course, though the specific phospholipid formulation limits direct generalization to other lemon balm products.

lemon-balm-pmid-41777239Prospective open-label dose-comparison clinical study
Sourceopen_in_new

Rondanelli M, Mazzola G, Barrile GC, Misiano P, Perna S. Melissa phospholipids improves sleep quality and mental well-being: concluding results from clinical study in adults with emotional distress. Food Nutr Res. 2026;70. doi:10.29219/fnr.v70.13729. PMID:41777239.

Population: Adults with poor sleep quality and or clinically significant emotional distress.

Dose protocol: Melissa phospholipids 200 mg/day or 400 mg/day for 3 weeks in adults with poor sleep quality or emotional distress

Key findings: Sleep improved in both groups, with a larger PSQI reduction at 400 mg/day, and the higher dose also reduced depression, anxiety, and stress scores without reported adverse effects.

Notes: Open-label dose-comparison study. Useful for dose-response context, but lower confidence than blinded trials.

Paper content

This 3-week open-label dose-comparison study enrolled 32 adults with poor sleep quality or emotional distress and tested Melissa phospholipids at 200 mg/day or 400 mg/day. Sleep improved in both groups, but the 400 mg/day arm showed the larger and faster effect, with roughly 30% improvement in PSQI versus 15% at the lower dose. The higher dose also improved depression, anxiety, stress, wellbeing, and quality-of-life scores without a detectable safety penalty. Because the study was open-label and lacked a placebo arm, it should not outweigh blinded lemon-balm trials, but it does strengthen the dose-response picture for phospholipid-based Melissa products.

lemon-balm-pmid-36502333Randomized, placebo-controlled, double-blind trial.
Sourceopen_in_new

Noguchi-Shinohara M, et al. Effects of Melissa officinalis Extract Containing Rosmarinic Acid on Cognition in Older Adults Without Dementia: A Randomized Controlled Trial. J Alzheimers Dis. 2023;91(2):805-814. doi:10.3233/JAD-220953. PMID:36502333.

Population: Older adults with subjective or mild cognitive impairment.

Dose protocol: Melissa officinalis extract (500 mg rosmarinic acid/day) for 96 weeks plus 24-week washout (n=323)

Key findings: No significant overall cognitive benefit on ADAS-cog. Subgroup analysis found cognitive preservation in participants without hypertension (P=0.036).

Notes: Largest and longest lemon balm human trial. Overall null primary result limits strong claims.

Paper content

This large (n=323) randomized placebo-controlled trial tested Melissa officinalis extract containing 500 mg rosmarinic acid daily for 96 weeks in older adults with subjective or mild cognitive impairment. The primary ADAS-cog analysis showed no significant overall difference between groups. However, a subgroup analysis found that among participants without hypertension, the lemon balm group maintained cognitive scores while the placebo group declined (P=0.036). The study is the largest and longest human trial of lemon balm for cognitive outcomes to date. The overall null primary result limits strong claims, though the subgroup finding suggests potential cognitive protection in normotensive older adults.

lemon-balm-SRC-001Randomized, double-blind, placebo-controlled parallel-group trial
Sourceopen_in_new

Mathews I, Eastwood J, Bell L, Lamport D, Le Cozannet R, Fanca-Berthon P, Williams C. The acute effects of Zensera™ (Melissa officinalis L.) extract on mood and cognitive performance during cognitive overload: a randomised placebo-controlled, double-blind study in healthy young adults with moderate subjective stress. Ther Adv Psychopharmacol. 2026;16:20451253261415706. doi:10.1177/20451253261415706. PMID:41782777.

Population: Healthy young adults with moderate subjective stress complaints.

Dose protocol: Single 300 mg Zensera extract versus placebo across a 5-hour cognitive-overload test day in 106 moderately stressed adults

Key findings: The primary overall-calmness endpoint was null, but Zensera improved the hardest executive-function trials at 5 hours and improved calmness recovery after demanding tasks.

Notes: Good corrective acute study because it supports stress-buffering and task-performance framing more than generic immediate calmness claims.

Paper content

This acute lemon-balm trial randomized 106 moderately stressed adults to a single 300 mg dose of Zensera or placebo before a day of repeated cognitive-overload testing. The primary calmness endpoint was null, which matters because it prevents overclaiming generic anxiolysis. Even so, the active treatment improved the hardest executive-function trials at 5 hours and helped restore transient calmness after demanding task blocks. The study sharpens lemon balm's positioning: acute benefits may be more about buffering stress-related cognitive fatigue and mood recovery than producing an obvious immediate tranquilizing effect.

Guides

Setup

Help